GeneHealth - Your precision medicine

Atm-related Disorder

Disease Details

Family Health Simplified

Buy Membership

Description: ATM-related disorder, also known as Ataxia-Telangiectasia (A-T), is a rare, inherited neurodegenerative disease that affects various systems in the body, leading to progressive difficulty with movement coordination, weakened immune system, and higher risk of cancers.
Type: Ataxia-telangiectasia (ATM-related disorder) is an autosomal recessive genetic disorder.
Signs And Symptoms: Ataxia-telangiectasia (ATM-related disorder) is a rare, inherited condition that affects various systems in the body. Here are the signs and symptoms:

1. **Neurological Symptoms:**
- Progressive ataxia (lack of muscle coordination).
- Slurred speech.
- Difficulty with fine motor skills.
- Chorea (involuntary, rapid movements).

2. **Telangiectasia:**
- Red, spider-like veins, usually noticeable in the eyes and on the skin.

3. **Immune System:**
- Increased susceptibility to infections.
- Recurrent respiratory infections.

4. **Growth and Development:**
- Delayed growth.
- Delayed or halted sexual development.

5. **Increased Cancer Risk:**
- Higher risk of developing cancers, particularly lymphomas and leukemias.

6. **Other Symptoms:**
- Sensitivity to radiation (e.g., X-rays).
- Difficulty swallowing.
- Diabetes-related issues like glucose intolerance in some cases.
Prognosis: ATM-related disorder, often referred to as Ataxia-Telangiectasia (A-T), is a rare, inherited neurodegenerative disease. Prognosis is generally poor:

1. **Onset and Progression**: Symptoms typically start in early childhood and progressively worsen. Individuals commonly require wheelchair use by adolescence.

2. **Life Expectancy**: Life expectancy is reduced, with many individuals surviving into their second or third decade. Advances in supportive care have slightly improved this.

3. **Complications**: The disorder leads to a high risk of infections, mainly respiratory, and increased susceptibility to cancers, particularly lymphomas and leukemias.

Early diagnosis and supportive treatments can help manage symptoms and improve quality of life but do not alter the disease's progressive nature.
Onset: ATM-related disorder, also known as Ataxia-Telangiectasia (A-T), typically has its onset in early childhood, usually between ages 1 and 4. It is a rare genetic condition that progressively affects various body systems. Although the age of onset can be variable, early symptoms often include motor impairments such as unsteady walking (ataxia) and difficulty with coordination.
Prevalence: Ataxia-Telangiectasia (A-T), an inherited disorder caused by mutations in the ATM gene, is estimated to have a prevalence of approximately 1 in 40,000 to 1 in 100,000 live births worldwide.
Epidemiology: ATM-related disorder, most notably ataxia-telangiectasia (A-T), is a rare inherited condition caused by mutations in the ATM gene. It affects approximately 1 in 40,000 to 100,000 live births worldwide. The disorder commonly manifests during early childhood and is characterized by progressive neurological deterioration, impaired immune function, a high risk of malignancies (especially lymphomas and leukemias), and sensitivity to ionizing radiation.
Intractability: Ataxia-telangiectasia (A-T) is considered an intractable disorder. It is a rare, progressive, neurodegenerative disease caused by mutations in the ATM gene. Current treatments focus on managing symptoms and complications, as there is no cure. Research is ongoing to find more effective therapies and potential cures.
Disease Severity: Ataxia-telangiectasia (AT) is a rare, inherited disorder that affects various systems in the body, primarily the nervous and immune systems. The severity of the disease can vary among individuals, but it is generally considered severe. Children with AT often develop significant neurological impairments, such as difficulty with walking, coordination, and balance. They are also at increased risk for infections due to immunodeficiency and have a higher susceptibility to cancers, particularly leukemia and lymphoma. The condition tends to worsen over time, leading to progressive disability. Life expectancy may be reduced, with many individuals affected by AT living into their twenties or thirties.
Pathophysiology: ATM-related disorders involve mutations in the ATM gene, which encodes a protein crucial for the repair of double-strand DNA breaks. In its absence or malfunction, cells are unable to effectively repair DNA damage, leading to genomic instability. This predisposes individuals to various cancers and affects normal cellular functions, resulting in conditions like Ataxia-Telangiectasia.
Carrier Status: Ataxia Telangiectasia (ATM-related disorder) is a rare, inherited condition caused by mutations in the ATM gene. The disorder follows an autosomal recessive inheritance pattern.

### Carrier Status
- Individuals with one mutated copy of the ATM gene and one normal copy are considered carriers.
- Carriers typically do not exhibit symptoms of the disease.
- Carriers have a 50% chance of passing the mutated gene to their offspring.

### NAN (Not Available or Not Applicable)
- If "NAN" refers to the lack of specific information requested, please clarify the inquiry for more detailed support.
Mechanism: Ataxia-telangiectasia (A-T) is primarily associated with mutations in the ATM (Ataxia-Telangiectasia Mutated) gene. The ATM gene encodes for a protein kinase that is pivotal in orchestrating the cellular response to DNA damage, particularly double-strand breaks. When DNA damage is detected, the ATM protein is activated through autophosphorylation and subsequently phosphorylates several key substrates involved in DNA repair, cell cycle regulation, and apoptosis.

Key molecular mechanisms involved include:

1. **DNA Damage Response (DDR)**: ATM activates and phosphorylates critical proteins such as p53, CHK2, and BRCA1, which coordinate the repair of DNA double-strand breaks through homologous recombination and other repair pathways.

2. **Cell Cycle Control**: ATM-mediated phosphorylation of p53 can lead to cell cycle arrest, allowing cells time to repair DNA damage before proceeding through the cell cycle.

3. **Apoptosis**: If DNA damage is irreparable, ATM can promote apoptosis to prevent the propagation of damaged DNA.

Dysfunction in ATM due to mutations leads to compromised DNA repair, resulting in genomic instability, increased sensitivity to ionizing radiation, and higher susceptibility to cancer. Furthermore, defective cell cycle control contributes to the neurodegenerative and immune system deficiencies characteristic of ataxia-telangiectasia.
Treatment: Ataxia-telangiectasia (A-T) is a rare, inherited disorder that affects various body systems, particularly the nervous and immune systems. Treatment for A-T is generally supportive and symptomatic, as there is no cure. It includes:

1. **Neurological Care**: Physical, occupational, and speech therapies to manage motor symptoms and speech difficulties.
2. **Immune System Support**: Immunoglobulin replacement therapy for individuals with immunodeficiency to reduce the risk of infections.
3. **Respiratory Care**: Regular monitoring and management of respiratory issues, including physiotherapy and treatment of infections.
4. **Cancer Surveillance**: Increased screening for cancers, as individuals with A-T have a higher risk of developing malignancies.
5. **Medications**: Antioxidants and certain drugs may be prescribed to manage symptoms and slow disease progression.
6. **Nutritional Support**: Dietary modifications and supplements to ensure proper nutrition and manage swallowing difficulties.

Close monitoring by a team of specialists, including neurologists, immunologists, and pulmonologists, is essential for managing the condition effectively.
Compassionate Use Treatment: Ataxia-telangiectasia (A-T) is a rare, inherited disorder that affects multiple body systems, particularly the nervous and immune systems. Given the lack of definitive treatments, there are various compassionate use, off-label, and experimental treatments considered for managing symptoms and improving quality of life:

1. **Compassionate Use Treatments**:
- **NAC (N-acetylcysteine)**: An antioxidant that may reduce oxidative stress.
- **IGIV (Intravenous immunoglobulin)**: Used to boost immune system function.
- **Therapy for Infections**: Antibiotics and antifungals might be used to treat recurrent infections.

2. **Off-Label Treatments**:
- **Steroids (e.g., betamethasone, methylprednisolone)**: Used to help improve neurological symptoms.
- **ACE Inhibitors (e.g., losartan)**: To manage telangiectasia-related complications.

3. **Experimental Treatments**:
- **Gene Therapy**: Ongoing research is exploring the possibility of correcting the defective ATM gene.
- **Stem Cell Therapy**: Investigational studies are looking into the potential benefits of hematopoietic stem cell transplantation.
- **Erythrocyte-delivered dexamethasone sodium phosphate (EDSP)**: A Phase II trial is assessing its efficacy in neurological improvement.

Overall, these treatments focus on symptom relief and improving the quality of life for those with A-T. Always consult with healthcare providers for the most current and suitable treatment options.
Lifestyle Recommendations: For ataxia-telangiectasia (ATM-related disorder), lifestyle recommendations include:

1. **Regular Physical Therapy:** To maintain muscle strength and coordination.
2. **Balanced Diet:** To support overall health, potentially avoiding foods that might exacerbate symptoms.
3. **Avoidance of Alcohol and Tobacco:** To prevent further neurological or health complications.
4. **Preventive Care:** Regular check-ups to monitor for cancers and infections due to immune system deficiencies.
5. **Sun Protection:** Increased sensitivity to radiation requires diligent sun protection.
6. **Safety Measures:** Modifications in the home to avoid falls and injuries due to coordination issues.
7. **Vaccinations:** Keeping up-to-date with vaccinations to prevent infections.

Consultation with healthcare providers, including neurologists, physiotherapists, and dietitians, is advisable for a personalized management plan.
Medication: Ataxia-telangiectasia (A-T) does not have a cure, but treatment focuses on managing symptoms and improving quality of life. Medications may include immunoglobulin therapy to boost the immune system, antibiotics to prevent infections, and drugs to control seizures and movement disorders.
Repurposable Drugs: Ataxia-telangiectasia (AT) is a rare, neurodegenerative, autosomal recessive disorder caused by mutations in the ATM gene. While there is currently no cure for AT, some repurposable drugs have shown potential in mitigating symptoms or slowing disease progression:

1. **Dexamethasone** - This corticosteroid has been observed to improve neurological symptoms in some AT patients.
2. **Erythropoietin (EPO)** - Known primarily for its role in erythropoiesis, it may provide neuroprotective effects.
3. **Metformin** - Commonly used for type 2 diabetes, it has potential anti-inflammatory and neuroprotective properties.
4. **N-Acetylcysteine (NAC)** - An antioxidant that can help reduce oxidative stress, which is elevated in AT patients.
5. **Exendin-4** - A GLP-1 receptor agonist used in diabetes that may have neuroprotective effects.

These drugs are not curative but may help manage symptoms and improve quality of life for those with AT. Always consult with a healthcare professional before starting any new treatment.
Metabolites: Ataxia-telangiectasia (A-T) is the disorder related to ATM (ataxia-telangiectasia mutated) gene mutations. For individuals with A-T, abnormal metabolite profiles have been observed, including elevated levels of certain amino acids, such as glycine and serine, as well as changes in purine and pyrimidine metabolism. These metabolite alterations can contribute to some of the clinical manifestations of the disease.
Nutraceuticals: Ataxia-telangiectasia (A-T) is a rare genetic disorder that affects various systems, primarily the nervous and immune systems. Nutraceuticals such as vitamin E, coenzyme Q10, and alpha-lipoic acid have been studied for their potential to mitigate oxidative stress in A-T patients. However, comprehensive clinical evidence supporting their efficacy is still limited.

Nanotechnology-based approaches are in the early stages of research for A-T and primarily focus on targeted drug delivery systems. These approaches aim to enhance the effectiveness and reduce the side effects of drugs by delivering them specifically to the affected cells.

It's important for patients to consult healthcare professionals before considering nutraceuticals or any experimental treatments.
Peptides: Ataxia-telangiectasia mutated (ATM)-related disorder, commonly known as Ataxia-telangiectasia (A-T), is a rare, neurodegenerative, inherited disease. Peptides have been studied in various therapies to potentially modify or treat symptoms of different diseases, including genetic disorders like A-T. However, in the context of ATM-related disorders, the research focus primarily involves DNA repair mechanisms and the development of targeted therapies that can address the specific genetic mutations.

The use of nanoparticles (nan) in A-T treatment is also a promising area of research. Nanoparticles can potentially deliver drugs more effectively to specific cells or tissues, reducing side effects and improving therapeutic outcomes. These advances could lead to more precise and effective treatments for A-T and other similar genetic disorders.

While peptides and nanoparticles hold potential, current treatments primarily involve managing symptoms through physical therapy, immunoglobulin replacement therapy for immune deficiencies, and monitoring for cancer risk, which is higher in A-T patients.